Search: onr:"swepub:oai:DiVA.org:umu-97219" > One course of adjuv...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06348naa a2200685 4500 | |
001 | oai:DiVA.org:umu-97219 | |
003 | SwePub | |
008 | 141212s2014 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:f69f4c56-faa0-4731-bfae-d084e78b6a5d | |
009 | oai:DiVA.org:uu-239383 | |
009 | oai:DiVA.org:liu-112815 | |
009 | oai:prod.swepub.kib.ki.se:130075034 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-972192 URI |
024 | 7 | a https://doi.org/10.1093/annonc/mdu3752 DOI |
024 | 7 | a https://lup.lub.lu.se/record/46149262 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2393832 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1128152 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1300750342 URI |
040 | a (SwePub)umud (SwePub)lud (SwePub)uud (SwePub)liud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Tandstad, T.u St Olavs University Hospital, Norway4 aut |
245 | 1 0 | a One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group |
264 | 1 | b Elsevier BV,c 2014 |
338 | a print2 rdacarrier | |
500 | a Funding Agencies|National Cancer Fund of Sweden | |
520 | a The SWENOTECA group treated 517 clinical stage I nonseminoma patients with one course of adjuvant BEP in a prospective study. The median follow-up is 7.9 years. One course of adjuvant BEP reduced the risk of relapse by over 90%. The relapse rates were 1.6% in low-risk disease and 3.2% in high-risk disease. One course of adjuvant BEP should be considered a standard adjuvant treatment option.SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results. In a prospective, binational, population-based risk-adapted treatment protocol, 517 Norwegian and Swedish patients with CS I nonseminoma received one course of adjuvant BEP. Patients with lymphovascular invasion (LVI) in the primary testicular tumor were recommended one course of adjuvant BEP. Patients without LVI could choose between surveillance and one course of adjuvant BEP. Data for patients receiving one course of BEP are presented in this study. At a median follow-up of 7.9 years, 12 relapses have occurred, all with IGCCC good prognosis. The latest relapse occurred 3.3 years after adjuvant treatment. The relapse rate at 5 years was 3.2% for patients with LVI and 1.6% for patients without LVI. Five-year cause-specific survival was 100%. The updated and expanded results confirm a low relapse rate following one course of adjuvant BEP in CS I nonseminoma. One course of adjuvant BEP should be considered a standard treatment in CS I nonseminoma with LVI. For patients with CS I nonseminoma without LVI, one course of adjuvant BEP is also a treatment option. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a testicular cancer | |
653 | a adjuvant chemotherapy | |
653 | a nonseminoma | |
700 | 1 | a Ståhl, Olofu Lund University,Lunds universitet,Reproduktionsmedicin, Malmö,Forskargrupper vid Lunds universitet,Reproductive medicine, Malmö,Lund University Research Groups,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)kir-ost |
700 | 1 | a Håkansson, Ulfu Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)kir-uha |
700 | 1 | a Dahl, O.u University of Bergen, Norway; Haukeland Hospital, Norway4 aut |
700 | 1 | a Haugnes, H. S.u University of Tromso, Norway; University Hospital North Norway, Norway4 aut |
700 | 1 | a Klepp, O. H.u Alesund Hospital, Norway4 aut |
700 | 1 | a Langberg, C. W.u Oslo University Hospital, Norway4 aut |
700 | 1 | a Laurell, Annau Uppsala universitet,Enheten för onkologi,University of Uppsala Hospital, Sweden4 aut0 (Swepub:uu)annajohn |
700 | 1 | a Oldenburg, J.u Oslo University Hospital, Norway4 aut |
700 | 1 | a Solberg, A.u St Olavs University Hospital, Norway4 aut |
700 | 1 | a Söderström, Karinu The Cancer Clinic, Norrland University Hospital, Umeå,Norrland University Hospital, Sweden4 aut0 (Swepub:umu)kansom97 |
700 | 1 | a Cavallin-Ståhl, Evau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)onk-ecs |
700 | 1 | a Stierner, U.u Sahlgrens University Hospital, Sweden4 aut |
700 | 1 | a Wahlquist, R.u Oslo University Hospital, Norway4 aut |
700 | 1 | a Wall, Najmeu Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Onkologiska kliniken US4 aut0 (Swepub:liu)najwa86 |
700 | 1 | a Cohn-Cedermark, G.u Karolinska Institutet4 aut |
710 | 2 | a St Olavs University Hospital, Norwayb Reproduktionsmedicin, Malmö4 org |
773 | 0 | t Annals of Oncologyd : Elsevier BVg 25:11, s. 2167-2172q 25:11<2167-2172x 0923-7534x 1569-8041 |
856 | 4 | u https://doi.org/10.1093/annonc/mdu375 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/25114021?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1093/annonc/mdu375y FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-97219 |
856 | 4 8 | u https://doi.org/10.1093/annonc/mdu375 |
856 | 4 8 | u https://lup.lub.lu.se/record/4614926 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-239383 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-112815 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:130075034 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.